Fusion proteins comprising carriers that can induce a dual immune response

• US 6,911,206 B1
• Filed: 02/16/2000
• Issued: 06/28/2005
• Est. Priority Date: 02/17/1999
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc., Pfizer Products Incorporated (Pfizer Inc.)
• Original Assignee: Pfizer Inc., Pfizer Products Incorporated (Pfizer Inc.)
• Inventors: Campos, Manuel, Martinod, Serge, Durtschi, Becky A., Yule, Terecita D.
• Primary Examiner(s): FOLEY, SHANON A
• Application Number:
  US09/506,078
• Time in Patent Office: 1,959 Days
• Field of Search: 424/185.1, 424/195.11, 424/192.1, 424/198.1, 424/204.1, 424/229.1, 424/184.1, 424/546, 424/186.1, 435/360, 536/23.4, 536/23.51, 536/23.72, 536/23.1, 514/8, 530/313, 530/350, 530/387.3, 530/388.85, 530/395, 530/397, 530/398, 530/399, 436/87
• US Class Current: 424/192.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0006 Contraceptive vaccins; Vaccines against sex hormones
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 19/00 Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 7/23 Luteinising hormone-releasing hormone [LHRH]; Related peptides
• CPC Class Codes: C12N 2710/16722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate'"'"'s immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein. The subject invention also provides fusion proteins which comprise a proteinaceous portion (b) that is a carrier that is analogous to all or part of a BHV-1 antigen, which fusion proteins induce in a vertebrate vaccinated with an effective amount of such fusion protein an immune response that inhibits the activity of a peptide as recited in (a), above.

Claims

1. A fusion protein for producing an immune response in a vertebrate, which fusion protein comprises:

(a) a first proteinaceous portion comprising a peptide sequence of the gonadotropin releasing hormone (GnRH) peptide as set forth in SEQ ID NO;

13 connected to (b) a second proteinaceous portion comprising a polypeptide sequence of the Bovine Herpes Virus Type-1 (BHV-1) gD protein as set forth in SEQ ID NO;

29;

wherein the activity of said GnRH peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate and when the vertebrate is vaccinated with an effective amount of said fusion protein, the vertebrate recognizes said first proteinaceous portion (a) and induces an immune response capable of inhibiting the activity of said GnRH peptide within the vertebrate.

2. A fusion protein for producing an immune response in a vertebrate, which fusion protein comprises:

(a) a first proteinaceous portion comprising a peptide sequence of the GnRH peptide as set forth in SEQ ID NO;

13 connected to (b) a second proteinaceous portion comprising a polypeptide sequence of the BHV-1 gD protein as set forth in SEQ ID NO;

29;

wherein the activity of said GnRH peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate and when the vertebrate is vaccinated with an effective amount of said fusion protein, the vertebrate recognizes said first proteinaceous portion (a) and induces an immune response capable of inhibiting the activity of said GnRH peptide within the vertebrate.